Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Kaminski JM, Nguyen K, Buyyounouski M, Pollack A. Prostate cancer gene therapy and the role of radiation. Cancer Treat Rev. 2002 Feb;28(1):49-64.
Langer CJ. Elderly patients with lung cancer: biases and evidence. Current treatment options in oncology. 2002 Feb;3(1):85-102.
Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002 Aug;95(3):613-23.
Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute. 2002 Feb 06;94(3):173-81.
Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer letters. 2002 Oct 08;184(1):7-12.
Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer. 2002 May;2(1):43-50.
Martin VR. Ovarian cancer. Semin Oncol Nurs. 2002 Aug;18(3):174-83.
Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):40-5.
Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42.
Ozols RF. Update on the management of ovarian cancer. Cancer journal (Sudbury, Mass). 2002 May;8 Suppl 1:S22-30.
Ozols RF, Markman M, Thigpen JT. ICON3 and chemotherapy for ovarian cancer. Lancet (London, England). 2002 Dec 21;360(9350):2086-7; author reply 2088.
Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. The Journal of biological chemistry. 2002 Sep 20;277(38):35050-60.
Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-8.
Ruggeri BA, Robinson C, Angeles T, Wilkinson Jt, Clapper ML. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res. 2002 Jan;8(1):267-74.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15;20(12):2895-903.
Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50.
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8(10):3100-4.
Sweeney CW. Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clinical journal of oncology nursing. 2002 May;6(3):163-6.
Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clinical therapeutics. 2002 Jan;24 Suppl A:A31-40.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use Human drug therapy Female Antineoplastic Combined Chemotherapy Protocols pathology Antineoplastic Agents US Gov't Support-PHS Ovarian Neoplasms Male Non-US Gov't Support Aged administration & dosage adverse effects Lung Neoplasms Adult analogs & derivatives therapy Middle Age Combined Modality Therapy Paclitaxel 80 and over Aged Cisplatin Neoplasms Gene Therapy methods prevention & control mortality Non-Small-Cell Lung Carcinoma metabolism Carboplatin chemically induced Drug Dose-Response Relationship Cultured Tumor Cells Neoplasm Drug Resistance Fluorouracil Radiation-Protective Agents Time Factors Radiotherapy Drug Administration Schedule radiotherapy Case Report diagnosis Animal Treatment Outcome Anticarcinogenic Agents Randomized Controlled Trials adverse Amifostine Quality of Life Neoplasm Staging physiology Rats Survival Analysis antagonists & inhibitors drug effects Risk Factors Prognosis pharmacokinetics effects Cell Survival toxicity Area Under Curve Chelating Agents Breast Neoplasms Lymphocytic Leukemia-Chronic Phosphodiesterase Inhibitors Local Neoplasm Recurrence Fibroblast Growth Factor Receptors Aromatase Erythropoietin Oligonucleotide Array Sequence Analysis Aging use Unsaturated Dietary Fats Experimental Mammary Neoplasms Protective Agents Hematopoietic Stem Cell Transplantation Liver Neoplasms dosage Pain Genetic Vectors Peripheral Nervous System Diseases Prostatic Neoplasms Nude Mice Hemangiosarcoma Liver prevention & Sprague-Dawley Rats etiology Withholding Treatment Estradiol therapeutic Mesna Isoenzymes Oral Administration Patient Care Planning Sulindac Cell Division statistics & numerical data Sulfonamides Retrospective Studies Antineoplastic Antimetabolites Heterologous Transplantation Hemoglobins US Gov't Support-Non-PHS Blood Transfusion Pancreatic Ribonuclease Thiazoles Platinum Compounds Evidence-Based Medicine Immunologic Adjuvants Goserelin Oncologic Nursing Squamous Cell Carcinoma Alanine Transaminase Pathologic Neovascularization pharmacology Vascular Endothelium Dietary Fats Lactones Theoretical Models Conformal Radiotherapy Razoxane Anemia Forecasting Prejudice Vascular Endothelial Growth Factor Receptors secondary Cyclooxygenase Inhibitors trends Aspartate Aminotransferases Etoposide Gene Transfer Techniques Confidence Intervals Survival Rate Mice Tissue Distribution Radiopharmaceuticals Cyclophosphamide Enzyme Inhibitors control Drug Monitoring Methylnitrosourea Non-Hodgkin Lymphoma Vidarabine Nerve Tissue Proteins Growth Factor Receptors complications Hormonal Antineoplastic Agents
Last updated on Friday, January 03, 2020